- Update on the Pharmacologic Agents for Dyslipidemia
-
Lee SH
- KMID: 2173853
- J Korean Diabetes.
- 2015 Dec;16(4):269-275.
- doi: 10.4093/jkd.2015.16.4.269
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia.... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
-
Lee SH
- KMID: 2413284
- Endocrinol Metab.
- 2017 Mar;32(1):36-40.
- doi: 10.3803/EnM.2017.32.1.36
In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of... -
- CITED
-
- Close
- SHARE
-
- Close
- Human spermatozoa anti-proprotein convertase subtilisin/kexin type 4 synthesis using New Zealand rabbit for novel immunocontraception in males
-
Dahril , Aulanni'am , Keumala V, Mustafa A
- KMID: 2450548
- Investig Clin Urol.
- 2019 Jul;60(4):303-311.
- doi: 10.4111/icu.2019.60.4.303
PURPOSE: Proprotein convertase subtilisin/kexin type 4 (PCSK4, a 54-kDa protease) is expressed in the plasma membrane of the acrosome in human spermatozoa. It plays a critical role in penetrating the... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
-
Choi JY, Na JO
- KMID: 2458383
- J Lipid Atheroscler.
- 2019 Sep;8(2):183-191.
- doi: 10.12997/jla.2019.8.2.183
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended... -
- CITED
-
- Close
- SHARE
-
- Close
- Detection of Familial Hypercholesterolemia Using Next Generation Sequencing in Two Population-Based Cohorts
-
Kim HN, Kweon SS, Shin MH
- KMID: 2458582
- Chonnam Med J.
- 2018 Jan;54(1):31-35.
- doi: 10.4068/cmj.2018.54.1.31
We aimed to evaluate the prevalence of familial hypercholesterolaemia (FH) in a subject with hypercholesterolaemia from two population-based cohorts in South Korea. A total of 283 subjects with total cholesterol... -
- CITED
-
- Close
- SHARE
-
- Close
- How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors
-
Lee EY, Yoon KH
- KMID: 2416253
- J Lipid Atheroscler.
- 2018 Jun;7(1):1-11.
- doi: 10.12997/jla.2018.7.1.1
Based on evidence from numerous research studies, increased low-density lipoprotein cholesterol (LDL-C) is a clinically important factor for accelerated atherosclerosis and increased cardiovascular risk. The introduction of statin therapy has... -
- CITED
-
- Close
- SHARE
-
- Close
- Associations for BCO2, PCSK9, and TR1B1 Polymorphism and Lifestyle Factors with Ischemic Stroke: A Nested Case-Control Study
-
Zhao TY, Li Z, Lei S, Huang L, Yang L
- KMID: 2450406
- Yonsei Med J.
- 2019 Jul;60(7):659-666.
- doi: 10.3349/ymj.2019.60.7.659
PURPOSE: To investigate associations for polymorphisms in β-carotene 9′,10′-oxygenase (BCO2, rs10431036 and rs11214109), proprotein convertase subtilisin kexin type 9 (PCSK9, rs11583680), and tribbles pseudokinase 1 (TRIB1, rs17321515 and rs2954029), as... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome
-
Bae KH, Kim SW, Choi YK, Seo JB, Kim N, Kim CY, Lee WK, Lee S, Kim JG, Lee IK, Lee JH, Park KG
- KMID: 2413983
- Diabetes Metab J.
- 2018 Jun;42(3):207-214.
- doi: 10.4093/dmj.2017.0081
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor. PCSK9 has emerged as a target for lipid-lowering therapy, but... -
- CITED
-
- Close
- SHARE
-
- Close
- Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
-
Suh S, Jung CH, Hong SJ, Kim JS, Choi SH
- KMID: 2429828
- J Lipid Atheroscler.
- 2018 Dec;7(2):77-87.
- doi: 10.12997/jla.2018.7.2.77
Lowering serum low-density lipoprotein cholesterol (LDL-C) is the mainstay for reduction of risk of cardiovascular disease (CVD), the second most common cause of death in Korea. The 2015 Korean guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor
-
Min DK, Lee HS, Lee N, Lee CJ, Song HJ, Yang GE, Yoon D, Park SW
- KMID: 2163616
- Yonsei Med J.
- 2015 Sep;56(5):1251-1257.
- doi: 10.3349/ymj.2015.56.5.1251
PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low density lipoprotein receptor (LDLR) and promotes degradation of the LDLR. Inhibition of PCSK9 either by reducing its expression or... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
-
Nam CW, Kim DS, Li J, Baccara-Dinet MT, Li I, Kim JH, Kim CJ
- KMID: 2463483
- Korean J Intern Med.
- 2019 Nov;34(6):1252-1262.
- doi: 10.3904/kjim.2018.133
BACKGROUND/AIMS: Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed... -
- CITED
-
- Close
- SHARE
-
- Close
- A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
-
Kim YU, Kee P, Danila D, Teng BB
- KMID: 2466611
- Immune Netw.
- 2019 Dec;19(6):e41.
- doi: 10.4110/in.2019.19.e41
We previously demonstrated that atherogenic Ldlr(−/−)Apobec1(−/−) (LDb) double knockout mice lacking both low-density lipoprotein receptor (LDLR) and apolipoprotein B mRNA-editing catalytic polypeptide-1 (Apobec1) had increased serum IL-17 levels, with T... -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolites profiling and hypolipidemic/hypocholesterolemic effects of persimmon (Diosyros kaki Thumb.) by different processing procedures: in vitro and in vivo studies
-
Park SY, Oh EK, Lim Y, Shin JY, Jung HA, Park SY, Lee JH, Choe JS, Kwon O
- KMID: 2419498
- J Nutr Health.
- 2018 Aug;51(4):275-286.
- doi: 10.4163/jnh.2018.51.4.275
PURPOSE: Our previous study demonstrated that persimmon (Diospyros kaki Thumb.) at different stages of ripening provided different protective effects against high-fat/cholesterol diet (HFD)-induced dyslipidemia in rats. In this study, we... -
- CITED
-
- Close
- SHARE
-
- Close
